Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?

Journal of Diabetes Research
Irene Ruiz-TamayoX Mundet-Tuduri

Abstract

To assess prescribing practices of noninsulin antidiabetic drugs (NIADs) in T2DM with several major contraindications according to prescribing information or clinical guidelines: renal failure, heart failure, liver dysfunction, or history of bladder cancer. Cross-sectional, descriptive, multicenter study. Electronic medical records were retrieved from all T2DM subjects who attended primary care centers pertaining to the Catalan Health Institute in Catalonia in 2013 and were pharmacologically treated with any NIAD alone or in combination. Records were retrieved from a total of 255,499 pharmacologically treated patients. 78% of patients with some degree of renal impairment (glomerular filtration rate (GFR) < 60 mL/min) were treated with metformin and 31.2% with sulfonylureas. Even in the event of severe renal failure (GFR < 30 mL/min), 35.3% and 22.5% of patients were on metformin or sulfonylureas, respectively. Moreover, metformin was prescribed to more than 60% of patients with moderate or severe heart failure. Some NIADs, and in particular metformin, were frequently used in patients at high risk of complications when they were contraindicated. There is a need to increase awareness of potential inappropriate prescribing and to ...Continue Reading

References

Sep 7, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·A HolsteinE H Egberts
Jul 27, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·A M Emslie-SmithUNKNOWN DARTS/MEMO Collaboration
Feb 28, 2002·Archives of Internal Medicine·Amy T CalabreseR Harsha Rao
Jun 22, 2002·The Cochrane Database of Systematic Reviews·S SalpeterE Salpeter
Jun 14, 2003·The Cochrane Database of Systematic Reviews·S SalpeterE Salpeter
Jul 3, 2003·JAMA : the Journal of the American Medical Association·Frederick A MasoudiHarlan M Krumholz
Jul 28, 2004·Diabetes Care·Gregory A NicholsJonathan B Brown
Sep 1, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·James McCormackHugh Tildesley
Sep 1, 2007·BMJ : British Medical Journal·Dean T EurichJeffrey A Johnson
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
May 27, 2010·Diabetes/metabolism Research and Reviews·Paolo PozzilliStefano Del Prato
Apr 12, 2013·Cardiovascular Diabetology·Diethelm TschöpePetra-Maria Schumm-Draeger
Nov 22, 2013·The Annals of Pharmacotherapy·Wenya R LuAmy Braun
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Dec 24, 2014·JAMA : the Journal of the American Medical Association·Silvio E InzucchiDarren K McGuire

❮ Previous
Next ❯

Citations

Aug 25, 2017·Clinical Drug Investigation·Weiyi HuangGregory M Peterson
Aug 20, 2020·JBI Evidence Synthesis·Mohammed B AyalewM Joy Spark

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

StataCorp
SIDIAP
Stata

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.